Wells J R, Hillier A, Holland R, Mwacalimba K, Noli C, Panter C, Tatlock S, Wright A
Patient-Centered Outcomes, Adelphi Values Ltd, Bollington, UK.
Clinical Outcomes Assessment Department, Sanofi, UK.
Vet Dermatol. 2024 Aug;35(4):386-399. doi: 10.1111/vde.13242. Epub 2024 Feb 15.
Animal and owner quality-of-life (QoL) is pivotal in treatment decisions. Accurate measurement of owner-reported QoL and treatment satisfaction (TS) supports disease burden and treatment benefit evaluation.
Develop and evaluate an owner-completed canine dermatitis QoL and TS questionnaire (CDQoL-TSQ) in allergic dogs.
The CDQoL-TSQ was drafted following review of existing measures and expert input. Content validity was assessed through interviews with owners of allergic dogs. Psychometric properties of the QoL domains (Canine QoL, Owner QoL) were evaluated. Score interpretation was derived.
Twenty dog owners were interviewed. Item wording was amended following the first 10 interviews. Data from 211 owners were used in the psychometric evaluation. The Canine QoL domain demonstrated strong internal consistency (α = 0.89), test-retest reliability (ICC = 0.844), moderate convergent validity (r = 0.41) and moderate-high known-groups validity (effect size 0.37-0.64). The Owner QoL domain demonstrated strong internal consistency (α = 0.73), high convergent validity (r = 0.63) and moderate-high known-groups validity (0.43-0.63). Test-retest reliability approached moderate strength (ICC = 0.490). Group-level interpretation analysis showed minimal important difference of 7.0-13.6 points for dogs and 13.0-13.6 for owners. For individual dogs a change of 6.3 or 12.5 points for dogs, and 12.5 or 18.8 for owners indicates a response.
The CDQOL-TSQ is a two-part assessment to evaluate QoL and TS in canine allergic dermatitis. The QoL questionnaire demonstrated validity and reliability, and interpretation of scores was derived, making it suitable for use in research and practice. The TS module is suitable for clinical setting use to improve owner-veterinarian communication.
动物和主人的生活质量(QoL)在治疗决策中至关重要。准确测量主人报告的生活质量和治疗满意度(TS)有助于评估疾病负担和治疗效果。
开发并评估一份供主人填写的犬过敏性皮炎生活质量和治疗满意度问卷(CDQoL-TSQ)。
在回顾现有测量方法并征求专家意见后起草了CDQoL-TSQ。通过与过敏性犬只的主人进行访谈来评估内容效度。对生活质量领域(犬生活质量、主人生活质量)的心理测量特性进行了评估。得出了分数解释。
对20位犬主进行了访谈。在前10次访谈后对项目措辞进行了修改。心理测量评估中使用了来自211位主人的数据。犬生活质量领域显示出很强的内部一致性(α = 0.89)、重测信度(ICC = 0.844)、中等的收敛效度(r = 0.41)和中等偏高的已知群体效度(效应大小0.37 - 0.64)。主人生活质量领域显示出很强的内部一致性(α = 0.73)、高收敛效度(r = 0.63)和中等偏高的已知群体效度(0.43 - 0.63)。重测信度接近中等强度(ICC = 0.490)。组水平解释分析表明,犬的最小重要差异为7.0 - 13.6分,主人为13.0 - 13.6分。对于个体犬只,犬的分数变化6.3或12.5分,主人的分数变化12.5或18.8分表明有反应。
CDQOL-TSQ是一个两部分的评估工具,用于评估犬过敏性皮炎的生活质量和治疗满意度。生活质量问卷显示出效度和信度,并得出了分数解释,使其适用于研究和实践。治疗满意度模块适用于临床环境,以改善主人与兽医之间的沟通。